First-Line Afatinib 30 mg <i>Versus</i> 40 mg in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutations: Real-world Efficacy and Tolerability in Taiwan
Afatinib 30 mg daily achieved comparable efficacy and better tolerability than 40 mg, with significantly longer PFS and OS in patients harboring compound or double-rare <i>EGFR</i> mutations. These findings suggest that lower-dose afatinib may optimize efficacy and safety in patients with uncommon <i>EGFR</i>-mutant NSCLC.
Authors
- Cheng-Hao Chuang
- Tai-Huang Lee
- Chung-Wen Huang
- M. H. Lee
- Yu-Chen Tsai (ORCID: https://orcid.org/0000-0002-0754-8672)
- C. Y. Yang
- Kuan-Li Wu
- Chia-Yu Kuo
- Jen-Yu Hung
- Inn-Wen Chong
- HK Huang
- Hui-Yang Hung
Institutions
- Kaohsiung Medical University (TW)
Publication Details
- Journal
- Anticancer Research
- Published
- 2026-01-30
- DOI
- https://doi.org/10.21873/anticanres.17999
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00